Long-acting injectable antipsychotics provide better outcomes in bipolar disorder and older schizophrenia patients
A research team from the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has found that long-acting injectable (LAI) antipsychotics provide better treatment outcomes than oral antipsychotic medications for patients 65 and older with schizophrenia.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
